MedTrace Logo

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

NCT00256100 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-04-12

No results posted yet for this study

Summary

The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.

Conditions

  • Renal Failure

Interventions

DRUG

Fondaparinux Sodium

The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation

Sponsors & Collaborators

  • Melbourne Health

    lead OTHER

Principal Investigators

  • John F Cade · Melbourne Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00256100 on ClinicalTrials.gov